Recently completed and ongoing studies involving antiplatelet agents
| Study title . | Clinical trials #/Phase . | Intervention . | Status . | Primary sponsor . |
|---|---|---|---|---|
| Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis | NCT01932554 Phase 2 | Abciximab | Withdrawn | St. Louis Univ. |
| Dipyridamole/Magnesium To Improve Sickle Cell Hydration | NCT00276146 Phase 2 | Dipyridamole, Magnesium | Withdrawn | Children's Hospital Medical Center, Cincinnati |
| A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Eptifibatide as Treatment of Acute Pain Episodes in Sickle Cell Disease | NCT00834899 Phase 1, 2 | Eptifibatide | Terminated | Univ. of North Carolina-Chapel Hill |
| An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults | NCT01178099 Phase 1 | Prasugrel | Completed | Ely Lilly |
| A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease | NCT01476696 Phase 2 | Prasugrel | Completed | Ely Lilly |
| Prasugrel Versus Placebo in Adult Sickle Cell Disease | NCT01167023 Phase 2 | Prasugrel | Completed | Ely Lilly |
| A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease. | NCT01794000 Phase 3 | Prasugrel | Active, not recruiting | Eli Lilly |
| Aspirin Prophylaxis in Sickle Cell Disease | NCT00178464 Phase 1, Phase 2 | Aspirin | Completed | Univ. of Rochester |
| A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor Followed by a 4 Weeks Extension Phase in Pediatric Patients With Sickle Cell Disease | NCT02214121 Phase 2 | Ticagrelor | Recruiting | AstraZeneca |
| A Study to Evaluate the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease (Hestia2) | NCT02482298 Phase 2 | Ticagrelor | Recruiting | AstraZeneca |
| Study title . | Clinical trials #/Phase . | Intervention . | Status . | Primary sponsor . |
|---|---|---|---|---|
| Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis | NCT01932554 Phase 2 | Abciximab | Withdrawn | St. Louis Univ. |
| Dipyridamole/Magnesium To Improve Sickle Cell Hydration | NCT00276146 Phase 2 | Dipyridamole, Magnesium | Withdrawn | Children's Hospital Medical Center, Cincinnati |
| A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Eptifibatide as Treatment of Acute Pain Episodes in Sickle Cell Disease | NCT00834899 Phase 1, 2 | Eptifibatide | Terminated | Univ. of North Carolina-Chapel Hill |
| An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults | NCT01178099 Phase 1 | Prasugrel | Completed | Ely Lilly |
| A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease | NCT01476696 Phase 2 | Prasugrel | Completed | Ely Lilly |
| Prasugrel Versus Placebo in Adult Sickle Cell Disease | NCT01167023 Phase 2 | Prasugrel | Completed | Ely Lilly |
| A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease. | NCT01794000 Phase 3 | Prasugrel | Active, not recruiting | Eli Lilly |
| Aspirin Prophylaxis in Sickle Cell Disease | NCT00178464 Phase 1, Phase 2 | Aspirin | Completed | Univ. of Rochester |
| A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor Followed by a 4 Weeks Extension Phase in Pediatric Patients With Sickle Cell Disease | NCT02214121 Phase 2 | Ticagrelor | Recruiting | AstraZeneca |
| A Study to Evaluate the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease (Hestia2) | NCT02482298 Phase 2 | Ticagrelor | Recruiting | AstraZeneca |